Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11746783 | 0.84 | KDM4E (0.46) | ALDH1A1MEN1KMT2AADRB2KDM4E | |
| SCHEMBL22200743 | 0.80 | KDM4E (0.56) | ALDH1A1MEN1KMT2AADRB2KDM4E | |
| SCHEMBL11745832 | 0.79 | NPSR1 (0.55) | ALDH1A1MEN1KMT2AADRB2KDM4E | |
| SCHEMBL10864958 | 0.79 | CYP3A4 (0.61) | ALDH1A1MEN1KMT2AADRB2KDM4E | |
| SCHEMBL17472737 | 0.79 | IDO1 (0.43) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL11716392 | 0.78 | MCOLN3 (0.49) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL11776518 | 0.78 | HPGD (0.48) | ALDH1A1MEN1KMT2AADRB2KDM4E | |
| SCHEMBL11216330 | 0.76 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AADRB2KDM4E | |
| SCHEMBL13034132 | 0.76 | ADRB2 (0.57) | ALDH1A1MEN1KMT2AADRB2SMN1; SMN2 | |
| SCHEMBL365584 | 0.76 | LMNA (0.51) | ALDH1A1MEN1KMT2AADRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098212-B2 | Piperazine derivatives | BLUMBERG LAURA C | 2006-08-29 | — | — | US | disclosed |
| EP-1583533-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1438298-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | Pfizer Products Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040092529-A1 | Methods of using piperazine derivatives | PFIZER INC | 2004-05-13 | — | — | US | disclosed |
| WO-2004039376-A1 | USE OF PIPERAZINE DERIVATIVES AS CCR1 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040034034-A1 | Novel piperazine derivatives | BLUMBERG LAURA C (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2003035627-A1 | PIPERAZINE DERIVATIVES WITH CCR1 RECEPTOR ANTAGONIST ACTIVITY | PFIZER PRODUCTS INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092529-A1 | Methods of using piperazine derivatives | CCR1, CCR3, CCR5 | ALDH1A1 238/4885MEN1 4618/4885KMT2A 4125/4885 |
| US-20040034034-A1 | Novel piperazine derivatives | CCR1, CCRL2, CCR5 | ALDH1A1 373/4885MEN1 4737/4885KMT2A 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.